190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

Park K 1 , Han JY 2 , Kim DW 3 , Bazhenova LA 4 , Ou SH 5 , Pang YK 6 Show all authors , Hin HS 7 , Juan O 8 , Son J 9 , Jänne P 10

Affiliations 

  • 1 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  • 2 Center for Lung Cancer, National Cancer Center, Goyang, Republic of Korea
  • 3 Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
  • 4 Department of Medicine, University of California San Diego Moores Cancer Center, La Jolla, CA, USA
  • 5 Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA
  • 6 Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 7 Department of Internal Medicine, International Islamic University Malaysia, Pahang, Malaysia
  • 8 Servicio de Oncología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
  • 9 R&D, Hanmi Pharmaceutical Co., Seoul, Republic of Korea
  • 10 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
J Thorac Oncol, 2016 Apr;11(4 Suppl):S139.
PMID: 27198328 DOI: 10.1016/S1556-0864(16)30299-4

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications